Zobrazeno 1 - 10
of 196
pro vyhledávání: '"Ofri, Mosenzon"'
Autor:
Meir Schechter, Cheli Melzer Cohen, Alisa Fishkin, Aliza Rozenberg, Ilan Yanuv, Dvora R. Sehtman-Shachar, Gabriel Chodick, Alice Clark, Trine J. Abrahamsen, Jack Lawson, Avraham Karasik, Ofri Mosenzon
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-12 (2023)
Abstract Background In clinical trials enrolling patients with type 2 diabetes (T2D) at high cardiovascular risk, many glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improved albuminuria status and possibly mitigated kidney function loss. Howe
Externí odkaz:
https://doaj.org/article/9521c0be51314f39acf728abf59b4868
Autor:
Ildiko Lingvay, Ofri Mosenzon, Katelyn Brown, Xuewei Cui, Ciara O’Neill, Laura Fernández Landó, Hiren Patel
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-10 (2023)
Abstract Background Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide/ glucagon-like peptide-1 receptor agonist, is approved in the United States, Europe and Japan for the treatment of type 2 diabetes. Across the SURPASS-1 to -5
Externí odkaz:
https://doaj.org/article/4cc69da4844c471b9f872fa4f70bc5ba
Autor:
Adrian Covic, Marcus Säemann, Jean Filipov, Ryszard Gellert, Niels Gobin, Bojan Jelaković, Kairat Kabulbayev, Merike Luman, Marius Miglinas, Ofri Mosenzon, Adrián Okša, Milan Radovic, Benaya Rozen-Zvi, Ieva Ziediņa, Vladimir Tesar
Publikováno v:
Kidney & Blood Pressure Research, Pp 1-1 (2024)
Background: Chronic kidney disease (CKD) has a global prevalence of 9.1–13.4%. Comorbidities are abundant and may cause and affect CKD. Cardiovascular disease strongly correlates with CKD, increasing the burden of both diseases. Summary: As a group
Externí odkaz:
https://doaj.org/article/d98962fca9ec450ba78bb02ede6c7a06
Publikováno v:
Journal of Stroke, Vol 25, Iss 1, Pp 26-38 (2023)
Stroke is a major cause of death and long-term disability worldwide. Diabetes is associated with an increased risk of cardiovascular complications, including stroke. People with diabetes have a 1.5–2 times higher risk of stroke compared with people
Externí odkaz:
https://doaj.org/article/9f949d1459a247f9a40e2aa6cf7d5157
Autor:
Ofri Mosenzon, Matthew S. Capehorn, Alessandra De Remigis, Søren Rasmussen, Petra Weimers, Julio Rosenstock
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-12 (2022)
Abstract Background Exploratory analysis to determine the effect of semaglutide versus comparators on high-sensitivity C-reactive protein (hsCRP) in subjects with type 2 diabetes. Methods Trials of once-weekly subcutaneous (SUSTAIN 3) and once-daily
Externí odkaz:
https://doaj.org/article/0265b900f86546dc8af079861b61ce94
Autor:
Meir Schechter, Cheli Melzer Cohen, Ilan Yanuv, Aliza Rozenberg, Gabriel Chodick, Johan Bodegård, Lawrence A. Leiter, Subodh Verma, Hiddo J. Lambers Heerspink, Avraham Karasik, Ofri Mosenzon
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-9 (2022)
Abstract Background Type-2 diabetes (T2D), chronic kidney disease, and heart failure (HF) share epidemiological and pathophysiological features. Although their prevalence was described, there is limited contemporary, high-resolution, epidemiological
Externí odkaz:
https://doaj.org/article/f4e41b35e48048809e9286d06c138961
Autor:
Aviram Kogot-Levin, Yael Riahi, Ifat Abramovich, Ofri Mosenzon, Bella Agranovich, Liat Kadosh, Rachel Ben-Haroush Schyr, Doron Kleiman, Liad Hinden, Erol Cerasi, Danny Ben-Zvi, Ernesto Bernal-Mizrachi, Joseph Tam, Eyal Gottlieb, Gil Leibowitz
Publikováno v:
JCI Insight, Vol 8, Iss 7 (2023)
Diabetes is associated with increased risk for kidney disease, heart failure, and mortality. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) prevent these adverse outcomes; however, the mechanisms involved are not clear. We generated a roadmap of
Externí odkaz:
https://doaj.org/article/49358b6776da4385b24f9cb12f16a15f
Autor:
Meir Schechter, Cheli Melzer-Cohen, Aliza Rozenberg, Ilan Yanuv, Gabriel Chodick, Avraham Karasik, Mikhail Kosiborod, Ofri Mosenzon
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-12 (2021)
Abstract Background Randomized controlled trials showed that sodium/glucose cotransporter-2 inhibitors (SGLT2i) protect the heart and kidney in an array of populations with type 2 diabetes (T2D) and increased cardiorenal risk. However, the extent of
Externí odkaz:
https://doaj.org/article/183d926e22824f2198fce8d59b95f101
Autor:
Ofri Mosenzon, Abdullah Alguwaihes, Jose Luis Arenas Leon, Fahri Bayram, Patrice Darmon, Timothy M. E. Davis, Guillermo Dieuzeide, Kirsten T. Eriksen, Tianpei Hong, Margit S. Kaltoft, Csaba Lengyel, Nicolai A. Rhee, Giuseppina T. Russo, Shinichiro Shirabe, Katerina Urbancova, Sergio Vencio, the CAPTURE Study Investigators
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-13 (2021)
Abstract Background There is a paucity of global data on cardiovascular disease (CVD) prevalence in people with type 2 diabetes (T2D). The primary objective of the CAPTURE study was to estimate the prevalence of established CVD and its management in
Externí odkaz:
https://doaj.org/article/67a5ab1adb4e4cf9b4f165303e5e0c48
Autor:
Ofri Mosenzon, Stefano Del Prato, Meir Schechter, Lawrence A. Leiter, Antonio Ceriello, Ralph A. DeFronzo, Itamar Raz
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-13 (2021)
Abstract During the last decade we experienced a surge in the number of glucose lowering agents that can be used to treat patients with type 2 diabetes. Especially important are the discoveries that sodium glucose co-transporter type 2 inhibitors (SG
Externí odkaz:
https://doaj.org/article/79f3680a60234f788c2aad9443e2342f